Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 3/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.49 |
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14685805 | 0.92 | ALB (0.52) | ALBFOLH1NOD1GLP1RSMN1; SMN2 | |
| SCHEMBL17359223 | 0.92 | ALB (0.52) | ALBFOLH1NOD1GLP1RSMN1; SMN2 | |
| SCHEMBL18710730 | 0.92 | ALB (0.56) | ALBFOLH1NOD1GLP1RSMN1; SMN2 | |
| SCHEMBL14118034 | 0.89 | FOLH1 (0.51) | ALBFOLH1NOD1GLP1R | |
| SCHEMBL20122043 | 0.88 | ALB (0.58) | ALBFOLH1NOD1GLP1RSMN1; SMN2 | |
| SCHEMBL12964947 | 0.88 | ALB (0.55) | ALBFOLH1NOD1GLP1RSMN1; SMN2 | |
| SCHEMBL14118103 | 0.88 | NOD1 (0.50) | ALBFOLH1NOD1GLP1REPHX2 | |
| SCHEMBL24174150 | 0.87 | GLP1R (0.57) | ALBFOLH1NOD1GLP1REPHX2 | |
| SCHEMBL15507483 | 0.87 | GLP1R (0.57) | ALBFOLH1NOD1GLP1REPHX2 | |
| SCHEMBL15002709 | 0.87 | GLP1R (0.57) | ALBFOLH1NOD1GLP1REPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008943-A1 | STABLE GLUCAGON ANALOGUES AND USE FOR TREATMENT OF HYPOGLYCAEMIA | NOVO NORDISK A/S (DK) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008943-A1 | STABLE GLUCAGON ANALOGUES AND USE FOR TREATMENT OF HYPOGLYCAEMIA | GLP1R, IAPP, GCG | ALB 2102/4885FOLH1 1307/4885NOD1 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.